Manish R Patel
Overview
Explore the profile of Manish R Patel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
150
Citations
5572
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Roeker L, Woyach J, Cheah C, Coombs C, Shah N, Wierda W, et al.
Blood
. 2024 Jun;
144(13):1374-1386.
PMID: 38861666
Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi). Patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) were treated with fixed-duration pirtobrutinib plus venetoclax (PV)...
12.
Chen J, Vincent M, Shepard D, Peereboom D, Mahalingam D, Battiste J, et al.
Commun Med (Lond)
. 2024 May;
4(1):95.
PMID: 38773224
Background: Preclinical studies have demonstrated that VT1021, a first-in-class therapeutic agent, inhibits tumor growth via stimulation of thrombospondin-1 (TSP-1) and reprograms the tumor microenvironment. We recently reported data from the...
13.
Patel M, Johnson M, Winer I, Arkenau H, Cook N, Samouelian V, et al.
Cancer Immunol Immunother
. 2024 Mar;
73(5):89.
PMID: 38554156
Background: Ezabenlimab (BI 754091) is a humanised monoclonal antibody targeting programmed cell death protein-1. We report results from open-label, dose-escalation/expansion, Phase I trials that evaluated the safety, maximum tolerated dose...
14.
Spry J, Siegel B, Bakermans C, Beaty D, Bell M, Benardini J, et al.
Astrobiology
. 2024 Mar;
24(3):230-274.
PMID: 38507695
As focus for exploration of Mars transitions from current robotic explorers to development of crewed missions, it remains important to protect the integrity of scientific investigations at Mars, as well...
15.
Falchook G, Patnaik A, Richardson D, Harvey R, Sharma M, Hafez N, et al.
Clin Ther
. 2024 Feb;
46(3):228-238.
PMID: 38423866
Purpose: The poly (ADP-ribose) polymerase inhibitor niraparib is indicated as maintenance treatment in patients with certain subtypes of advanced ovarian cancer, and is being investigated in patients with other solid...
16.
Desai J, Alonso G, Kim S, Cervantes A, Karasic T, Medina L, et al.
Nat Med
. 2023 Dec;
30(1):271-278.
PMID: 38052910
KRAS G12C mutation is prevalent in ~4% of colorectal cancer (CRC) and is associated with poor prognosis. Divarasib, a KRAS G12C inhibitor, has shown modest activity as a single agent...
17.
Luke J, Patel M, Blumenschein G, Hamilton E, Chmielowski B, Ulahannan S, et al.
Nat Med
. 2023 Oct;
29(11):2814-2824.
PMID: 37857711
Tebotelimab, a bispecific PD-1×LAG-3 DART molecule that blocks both PD-1 and LAG-3, was investigated for clinical safety and activity in a phase 1 dose-escalation and cohort-expansion clinical trial in patients...
18.
Haque T, Lopez Cadenas F, Xicoy B, Alfonso-Pierola A, Platzbecker U, Avivi I, et al.
Leuk Res
. 2023 Sep;
134:107390.
PMID: 37776843
Splicing factor (SF) gene mutations are frequent in myelodysplastic syndromes (MDS), and agents that modulate RNA splicing are hypothesized to provide clinical benefit. JNJ-64619178, a protein arginine methyltransferase 5 (PRMT5)...
19.
Sacher A, LoRusso P, Patel M, Miller Jr W, Garralda E, Forster M, et al.
N Engl J Med
. 2023 Aug;
389(8):710-721.
PMID: 37611121
Background: Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity. Methods: In a phase 1 study, we evaluated divarasib administered orally once...
20.
Vieito M, Moreno V, Spreafico A, Brana I, Wang J, Preis M, et al.
Clin Cancer Res
. 2023 Jul;
29(18):3592-3602.
PMID: 37491846
Purpose: In this first-in-human, Phase 1, open-label, multicenter study, we evaluated JNJ-64619178, a selective and potent PRMT5 inhibitor, in patients with advanced malignant solid tumors or non-Hodgkin lymphomas (NHL). The...